Navigation Links
Immunodeficient patients with secondary lung disease benefit from combined chemotherapy
Date:8/30/2012

A team of researchers at the Medical College of Wisconsin and Children's Hospital of Wisconsin Research Institute defined a new treatment for a potentially fatal lung disease in patients with a primary immunodeficiency known as common variable immunodeficiency (CVID).The findings are published in the Journal of Clinical Immunology.

Common variable immunodeficiency (CVID) is the most common primary immunodeficiency that requires regular treatment with medication, specifically immunoglobulin (antibodies) replacement therapy. With immunoglobulin therapy, deaths from infection in patients with CVID have decreased and deaths due to non-infectious complications have increased. One of the most frequent causes of death now in CVID is a lung disease known as granulomatous-lymphocytic interstitial lung disease (GLILD). In GLILD, white blood cells abnormally accumulate in the lung, which leads to a progressive decline in lung function and, eventually, respiratory failure. The researchers evaluated patients with GLILD to see if rituximab and azathioprine (combination chemotherapy) would improve pulmonary function and/or radiographic abnormalities by killing these white blood cells in the lung.

"The most common medication used for GLILD are corticosteroids but in our hands this type of medication did not clear the disease. Therefore, we designed therapy aimed at killing the specific type of lymphocytes, B cells and T cells, we found in abnormal numbers in the lung biopsies we examined. We reasoned if we killed the lymphocytes in the lung, lung function and radiographic abnormalities would both improve, which is what we found." said John M. Routes, M.D., professor and chief of asthma, allergy and immunology at the Medical College of Wisconsin (MCW), medical director of allergy/clinical immunology at Children's Hospital and researcher at the Research Institute.


'/>"/>

Contact: Maureen Mack
mmack@mcw.edu
414-955-4700
Medical College of Wisconsin
Source:Eurekalert

Page: 1

Related medicine news :

1. Study pinpoints malignant mesothelioma patients likely to benefit from drug pemetrexed
2. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
3. Confusion Over Diabetes Types Adds to Patients Woes
4. TAVI restricted to very old or very sick patients
5. Mayo study: Exercise can help cancer patients, but few oncologists suggest it
6. Exploring exercise benefits for breast cancer patients
7. Not all lung cancer patients who could benefit from crizotinib are identified by FDA-approved test
8. Early Stenting Best for Some Heart Patients: Study
9. Global platelet reactivity identifies high risk ACS patients
10. Global platelet reactivity and high risk ACS patients
11. TAVI improves quality of life in patients with severe aortic stenosis for at least 1 year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... york (PRWEB) , ... April 28, 2017 , ... ... to announce that Aditya Patel M.D. has joined the revolutionary endoscopic practice under ... and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt Technique created ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... April 28, 2017 , ... NuevaCare, a leading home ... as Millbrae, Burlingame, and Palo Alto, is proud to announce information upgrades to its ... bookmark and read organized content on topics such as home care (generally) as well ...
(Date:4/27/2017)... ... April 27, 2017 , ... Today, ... based in Denver, Colorado, announced an agreement to create the Jane and Leonard ... of the Jane and Leonard Korman Family Foundation. The collaboration leverages the strengths ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... , April 19, 2017 Global ... This report on the prostate cancer therapeutics market ... global market. Increasing prevalence of prostate cancer, launch ... in the development of new drugs & therapeutic ... cancer drug due to lesser side effects are ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology: